BioSpace News Archive

Business

Biopharma Money on the Move: November 4-10

Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

November 10, 2020
·
5 min read
·
Kate Goodwin
XPhyto Secures Exclusive Psychedelic Drug Development Agreement

Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for the development of psychedelic-based therapeutics

November 10, 2020
·
4 min read
BioCapital

Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19

AdCOVID, a Single-dose Intranasal Vaccine for COVID-19is Designed to Generate aBroad Immune Response Against COVID-19 with the Unique Ability to PromoteNasal Mucosal Immunity

November 10, 2020
·
10 min read
Genetown

NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

Eight of nine patients treated on the study to date showed tumor regression, including six of seven prior anti-PD-1 non-responders

November 10, 2020
·
10 min read
BioMidwest

Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors

Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated solid tumors.

November 10, 2020
·
2 min read
Business

Photocure ASA: Results for the third quarter of 2020

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 49.6 million in the third quarter of 2020, with the U.S. market continuing the COVID-19 rebound with a growth of 20%.

November 10, 2020
·
5 min read
Drug Development

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

Amgen and AstraZeneca announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe asthma.

November 10, 2020
·
18 min read
Policy

Pharnext 2019 Universal Registration Document Approved by AMF

Pharnext SA announced that its 2019 Universal Registration Document has been approved by the Autorité des Marchés Financiers on November 9, 2020 under number N° R. 20-029.

November 10, 2020
·
4 min read
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round.

November 10, 2020
·
8 min read
Business

IRRAS AB publishes Interim Report for the period January to September 2020

During the third quarter IRRAS made decisive progress in a number of areas.

November 10, 2020
·
3 min read